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 Abstract 
Tropomodulin1 (TMOD1), which regulates the length and depolymerization of actin 
filaments by binding to the pointed end of the actin filament, has been reported to be a 
powerful diagnostic marker for ALK-negative anaplastic large-cell lymphoma; however, 
little is known about the relevance of TMOD1 in the behaviors of oral squamous cell 
carcinoma (OSCC). We evaluated TMOD1 expression in OSCC-derived cell lines and 
primary OSCC samples (n=200) using quantitative reverse transcriptase-polymerase chain 
reaction, immunoblotting, and semiquantitative immunohistochemistry. We also analyzed 
the clinical correlation between TMOD1 expression status and clinical parameters in 
patients with OSCC and performed a prospective study using 40 primary OSCC samples. 
TMOD1 expression was up-regulated significantly (p<0.05) in OSCC in vitro and in vivo 
compared with normal counterparts. TMOD1 expression also was correlated significantly 
(p=0.0199 and p=0.0064, respectively) with regional lymph node metastasis (RLNM) and 
5-year survival rates. This prospective study also showed that high TMOD1 expression 
was seen in 12 (75%) of 16 cases in RLNM-positive patients and nine (37.5%) of 24 cases 
in RLNM-negative patients. The current data provided the first evidence that TMOD1 
expression is a critical biomarker for RLNM and prognosis of patients with OSCC.
 Introduction 
Oral squamous cell carcinoma (OSCC) is a frequently occurring neoplasm that is usually 
aggressive and has a poor prognosis (1). OSCC accounts for more than 50% of all head and 
neck SCC. The prognosis in advanced cases is poor, and 5-year survival rates of OSCC are 
below 50% (2,3). The 5-year survival rate is 90% for patients without metastasis but less 
than 40% for patients with metastasis, suggesting that regional lymph node metastasis 
(RLNM) is one of the most adverse prognostic factors (4-10). However, the mechanisms of 
metastasis are poorly understood (11). Therefore, molecular changes in a number of 
oncogenes and tumor suppressor genes associated with development of OSCC may be 
important clues for preventing this disease, and elucidating the molecular mechanisms 
involved in cancer metastasis is needed (3,4). 
 The tropomodulin family (TMOD1-4) is expressed differentially in a tissue-specific 
manner and is involved in regulating actin filament architecture in diverse cellular types 
(12). TMOD1-4 are 70% similar in amino acid sequence with different expression profiles 
(13) and contain an N-terminal unstructured domain and a C-terminal domain consisting of 
5 leucine-rich repeat motifs (14,15). TMOD1-4 inhibit elongation and depolymerization of 
actin filaments by binding to the pointed end of the actin filament (16-18). Among them, 
TMOD1 has two actin-binding regions and two tropomyosin-binding regions (19-22). 
Recent studies have reported that TMOD1 is a diagnostic marker for triple-negative 
breast cancers and ALK-negative anaplastic large-cell lymphoma (23,24); however, the 
role of TMOD1 in OSCC remains unknown. We present the results of measurements of 
TMOD1 levels in OSCC that are clinically and functionally linked to RLNM. 
 Materials and methods 
Ethics statement. The Ethical Committee of the Graduate School of Medicine, Chiba 
University (approval number, 236) approved the study protocol, which was performed in 
accordance with the tenets of the Declaration of Helsinki. All patients provided written 
informed consent. 
 
OSCC-derived cell lines and tissue specimens. Human OSCC-derived cell lines (HSC-2, 
HSC-3, HSC-4, Sa3, Ca9-22, Ho-1-u-1, Ho-1-N-1, KOSC-2, and SAS) were obtained from 
the Human Science Research Resources Bank (Osaka, Japan) or the RIKEN BioResource 
Center (Ibaraki, Japan) through the National BioResource Project of the Ministry of 
Education, Culture, Sports, Science and Technology in Japan. Primary cultured human 
normal oral keratinocytes (HNOKs) were obtained from healthy oral mucosal epithelial 
specimens collected from young patients at Chiba University Hospital (25-28). All cells were 
grown in Dulbecco’s modified Eagle medium (Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 50 units/ml of penicillin 
and streptomycin (Sigma-Aldrich).  
Two hundred primary OSCC specimens and patient-matched normal epithelial 
specimens were obtained during surgeries performed at Chiba University Hospital (Table 1). 
The resected tissues were fixed in 20% buffered formaldehyde solution for pathologic 
diagnosis and immunohistochemical (IHC) staining. We performed histopathological 
diagnosis of each OSCC sample according to the World Health Organization criteria at the 
Department of Pathology of Chiba University Hospital (29). The clinicopathological stages 
 were determined based on the TNM classification of the International Union against Cancer 
(30). 
 
mRNA expression analysis. Total RNA was isolated using Trizol Reagent (Invitrogen, 
Carlsbad, CA, USA), according to the manufacturer’s instructions. cDNA was generated 
using ReverTra Ace qPCR RT Master Mix (Toyobo Life Science, Osaka, Japan) according to 
the manufacturer’s instructions. Real-time quantitative reverse transcriptase-polymerase 
chain reaction (qRT-PCR) was performed in a 20-μl reaction volume using the LightCycler 
480 apparatus (Roche Diagnostics, Mannheim, Germany), according to the manufacturer’s 
protocol. The general amplification conditions were performed as described previously 
(31-33). Primers and universal probes were designed using the Universal Probe Library Assay 
Design Center (Roche Diagnostics), which speciﬁes the most suitable set. The primer 
sequences used for qRT-PCR were: TMOD1, forward, 5′- 
AGCTGAGGACCCTGGAAAAT-3′; reverse, 5′- GCAGGCAGCAGTGCATTAT-3′; and 
universal probe #42, and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward, 
5′-CATCTCTGCCCCCTCTGCTGA-3′; reverse, 5′-GGATGACCTTGCCCACAGCCT-3′; 
and universal probe #60. The transcript amount for TMOD1 was estimated from the 
respective standard curves and normalized to the GAPDH transcript amount determined in 
corresponding samples. 
 
Immunoblotting analysis. The cells were washed three times with cold phosphate buffered 
saline (PBS) and gently and briefly centrifuged. The cellular pellets were incubated at 4°C for 
 30 minutes in a lysis buffer (7 M urea, 2 M thiourea, 4% w/v CHAPS, and 10 mM Tris; pH 
7.4) with a proteinase inhibitor cocktail (Roche Diagnostics). The total protein concentration 
was measured using a dye-binding method based on the Bradford assay with Bio-Rad Protein 
Assay Dye Reagent Concentrate (Bio-Rad Laboratories, Hercules, CA, USA). 
Protein extracts were electrophoresed on 4-12% Bis-Tris gel and transferred to 
nitrocellulose membranes (Invitrogen) and blocked for 1 hour at room temperature with 
Blocking One (Nacalai Tesque, Inc., Kyoto, Japan). The membranes were washed three times 
with 0.1% Tween-20 in Tris-buffered saline (TBS-T) and incubated with affinity-purified 
rabbit anti-TMOD1 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
and mouse anti-GAPDH monoclonal antibody overnight at 4°C. The membrane was washed 
with TBS-T and incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse 
IgG as a secondary antibody (Promega, Madison, WI, USA), for 1 hour at room temperature. 
Finally, the membranes were detected using Super-Signal West Pico Chemiluminescent 
substrate (Thermo Fisher Scientific, Rockford, IL, USA), and immunoblotting was visualized 
by exposing the membranes to the ChemiDoc XRS Plus System (Bio-Rad Laboratories). The 
signal intensities were quantitated using the Image Lab system (Bio-Rad Laboratories). 
Densitometric TMOD1 protein data were normalized to GAPDH protein levels. 
 
Semiquantitative IHC. Semiquantitative IHC (sq-IHC) of 4-µm sections of 
paraffin-embedded OSCC clinical specimens was performed. Briefly, after paraffinization, 
hydration, activation of antigen, hydrogen peroxide quenching, and blocking, the clinical 
sections were incubated with rabbit anti-TMOD1 monoclonal antibody (Santa Cruz 
 Biotechnology) at 4°C in a moist chamber overnight. Upon incubation with the primary 
antibody, the specimens were washed three times with PBS and treated with Envision 
reagent (DAKO, Carpinteria, CA, USA) followed by color development in 
3,3’-diaminobenzidine tetrahydrochloride (DAKO). The slides then were counterstained 
lightly with hematoxylin, dehydrated with ethanol, cleaned with xylene, and mounted. To 
quantify the status of the TMOD1 protein expression in clinical samples, we used the sq-IHC 
scoring systems described previously (28,34-38). The mean percentages of positive tumoral 
cells were determined in at least three random fields in each section; the intensities of the 
TMOD1-immunoreactions were scored as follows: 0+, none; 1+, weak; 2+, moderate; and 
3+, intense. The staining intensity and the cellular numbers were multiplied to produce a 
TMOD1 sq-IHC score. To determine the cutoff points of the TMOD1 sq-IHC scores, we 
analyzed the OSCCs sq-IHC scores of 200 patients using receiver operating characteristic 
(ROC) curves. Two independent pathologists from Chiba University Hospital, neither of 
whom had knowledge of the patients’ clinical status, made these judgments. To calculate the 
5-year survival rate, we surveyed each patient’s life and month of death. 
 
Prospective study. To evaluate the effect of the cutoff value from RLNM by ROC curve 
analysis, we performed a prospective study using 40 primary OSCC specimens at Chiba 
University Hospital. We randomly selected 40 primary OSCC specimens and analyzed the 
correlation between RLNM and TMOD1 expression using sq-IHC. 
 
Statistical analysis. To compare the TMOD1 expression levels, statistical significance was 
 evaluated using the Mann-Whitney U-test. The relationships between the TMOD1 sq-IHC 
scores and clinicopathological profiles were evaluated using the Student’s t-test and the 
Mann-Whitney U-test. The 5-year survival rate was evaluated using the log-rank test. P<0.05 
was considered statistically significant. The data are expressed as the mean ± the standard 
error of the mean. 
 Results 
Up-regulation of TMOD1 in OSCC-derived cell lines. To investigate the expression status of 
TMOD1, we performed qRT-PCR and immunoblotting analyses using nine OSCC-derived 
cell lines (HSC-2, HSC-3, HSC-4, Sa3, Ca9-22, Ho-1-u-1, Ho-1-N-1, KOSC-2, and SAS) and 
HNOKs. TMOD1 mRNA was up-regulated significantly (p<0.05) in all OSCC-derived cell 
lines compared with the HNOKs (Fig. 1A). We also performed immunoblotting analysis to 
investigate the TMOD1 protein expression in the OSCC-derived cell lines and the HNOKs 
(Fig. 1B). A significant increase in TMOD1 protein expression was seen in all OSCC-derived 
cell lines compared with the HNOKs. 
 
Evaluation of TMOD1 expression in primary OSCCs. To investigate the expression status 
of TMOD1 in primary OSCCs and the relation to the clinicopathological characteristics, we 
analyzed the TMOD1 protein expression in primary OSCC specimens from 200 patients 
(Table 1) using the sq-IHC scoring system. We showed representative IHC results for 
TMOD1 protein in primary OSCCs (Fig. 2A) and normal oral tissue (Fig. 2B). Strong 
TMOD1 immunoreactivity was detected in the cytoplasm of primary OSCCs; however, 
normal oral tissue showed almost negative immunostaining. The TMOD1 protein 
expression of primary OSCCs was significantly (p<0.05) higher than in normal tissue (Fig. 
2C). The TMOD1 sq-IHC scores in OSCCs and adjacent normal oral tissues ranged from 
204.44 to 7.00 (median, 100.00) and 105.50 to 4.00 (median, 35.83), respectively.  
 
 Evaluation of TMOD1 expression in primary OSCCs by age at surgery, gender, primary 
tumoral size, histologic type, and vascular invasiveness. We did not find differences 
between TMOD1 protein expression and these clinical parameters (Fig. 3A-E) (age at 
surgery, p=0.181; gender, p=0.417; primary tumoral size, p=0.057; histologic type, 
p=0.073; or vascular invasion, p=0.558). 
 
Evaluation of TMOD1 expression in primary OSCCs by RLNM. The ROC curve analysis 
showed that the area under the curve (AUC) was 0.608 (95% confidence interval [CI], 
0.527-0.688; sensitivity, 65.8%; specificity, 57.5%) and the cutoff value was 100.00 (Fig. 
4A). The TMOD1 sq-IHC scores of the RLNM-negative patients and RLNM-positive 
patients ranged from 204.44 to 12.50 (median, 85.48) and 201.17 to 7.00 (median, 112.16), 
respectively. TMOD1 protein expression of primary OSCCs with RLNM was significantly 
(p=0.0199) higher than without RLNM (Fig. 4B). 
 
Evaluation of TMOD1 expression in primary OSCCs with 5-year survival. Using the cutoff 
value from RLNM from ROC curve analysis, the 5-year survival rates in the 
TMOD1-positive OSCCs (n=103) and the TMOD1-negative OSCCs (n=97) were 60.4% 
and 79.9%, respectively. The survival rates in the TMOD1-positive group were 
significantly (p=0.0064) lower than those in the TMOD1-negative group (Fig. 5).  
 
Prospective study of TMOD1 expression in primary OSCCs. To determine if the cutoff 
value of the TMOD1 IHC scores from RLNM (Fig. 4) are useful as a clinical indicator, we 
 prospectively assessed the correlation between RLNM and TMOD1 expression in 40 
patients with OSCC. High TMOD1 expression was seen in 12 (75%) of 16 RLNM-positive 
patients and nine (37.5%) of 24 RLNM-negative patients. Thus, TMOD1 expression was 
significantly (p=0.027) higher in the RLNM-positive patients (Table 2). 
 Discussion 
We found that TMOD1 was overexpressed frequently in OSCC in vitro and in vivo 
(p<0.05; Figs. 1, 2), and that TMOD1 expression in RLNM-positive patients with OSCC 
was significantly (p<0.05) greater than in RLNM-negative patients (Fig. 4). In addition, the 
survival rates in the TMOD1-positive patients were significantly lower than in the 
TMOD1-negative patients (Fig. 5). In the prospective study, high TMOD1 expression was 
seen in 12 (75%) of 16 RLNM-positive patients and nine (37.5%) of 24 RLNM-negative 
patients (Table 2). 
OSCCs are characterized by a high degree of local invasiveness and a high rate of 
RLNM in an early phase (39). A study reported recently that 37% of patients with OSCC 
had RLNM (40). The 5-year survival rate in RLNM-negative patients was 81%, whereas 
that in RLNM-positive patients was 57% (40). Metastasis represents a highly organized, 
non-random, organ-specific, and multistep process (41). Although many molecules, such as 
integrins and matrix metalloproteinases (MMPs), play key roles in cancer cell invasiveness 
and metastasis (42-44), the precise factors and mechanisms affecting its preferred migration 
and invasion into the regional lymph nodes are poorly understood. Overexpression of 
TMOD1, a novel target of NF-κB, induces the translocation of -catenin to nucleus, 
leading to activation of MMPs in triple-negative breast cancer samples (23). Since NF-κB 
signaling also relates to RLNM and tumor-induced lymphangiogenesis (45), TMOD1 may 
contribute to the cellular invasiveness and metastasis in OSCCs. 
In conclusion, the current results indicated that TMOD1 is overexpressed frequently 
in human oral cancer. TMOD1 overexpression is associated with RLNM and the 5-year 
 survival rate. The prospective study also confirmed the correlation between TMOD1 
expression and RLNM. While further studies are needed to study the NF-κB–TMOD1 axis 
in the cancer microenvironment, TMOD1 overexpression may directly affect tumoral 
metastasis in OSCCs, and TMOD1 may be a critical biomarker of RLNM and a therapeutic 
target to prevent metastasis in OSCCs. 
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 Legends 
Figure 1. Up-regulation of TMOD1 in OSCC-derived cell lines. (A) Quantification of TMOD1 
mRNA expression in OSCC-derived cell lines by qRT-PCR analysis. Significant (*p<0.05, 
Student’s t-test) up-regulation of TMOD1 mRNA is seen in nine OSCC-derived cell lines 
compared with the HNOKs. Data are expressed as the mean ± SEM of triplicate results (A). 
Immunoblotting analysis of TMOD1 protein in OSCC-derived cell lines. TMOD1 protein 
expression is up-regulated in OSCC-derived cell lines compared with that in the HNOKs. 
Densitometric TMOD1 protein data are normalized to the GAPDH protein levels. The values 
are expressed as percentages of the HNOKs (B). 
 
Figure 2. Evaluation of TMOD1 expression in primary OSCCs. Representative 
sq-IHC results of TMOD1 in primary OSCCs (A) and normal oral tissues (B). 
Original magnification, ×200. The status of TMOD1 protein expression in primary 
OSCCs (n=200) and normal counterparts by the sq-IHC scoring system. The 
TMOD1 sq-IHC scores for OSCCs and normal oral tissues range from 204.44 to 
7.00 (median, 100.00) and 105.50 to 4.00 (median, 35.83), respectively. TMOD1 
protein expression levels in OSCCs are significantly (*p<0.05, Student’s t-test) 
higher than in normal oral tissue (C).  
 
Figure 3. Evaluation of TMOD1 expression in primary OSCCs by various clinical 
parameters. The evaluation of TMOD1 expression based on the age at surgery shows 
that the optimal cutoff point in the ROC curve analysis is 152.6 (AUC, 0.556; 95% CI, 
 0.476-0.636; sensitivity, 88.8%; specificity, 25.5%). The TMOD1 OSCCs sq-IHC scores in 
patients under 70 years of age and over 70 years of age range from 204.44 to 24.00 (median, 
103.00) and 200.00 to 7.00 (median, 94.00), respectively. The TMOD1 protein expression 
in the primary OSCCs does not differ significantly (p=0.18, Student’s t-test) between the 
two age groups (A). Evaluation of TMOD1 expression in primary OSCCs by gender 
shows that the optimal cutoff point in the ROC curve analysis is 104.0 (AUC, 0.530; 95% 
CI, 0.445-0.616; sensitivity, 47.7%; specificity, 61.2%). The TMOD1 OSCCs sq-IHC 
scores in males and females range from 201.17 to 7.00 (median, 101.00) and 204.44 to 
12.50 (median, 89.92), respectively. The TMOD1 protein expression in the primary OSCCs 
does not differ significantly (p=0.417, Student’s t-test) between males and females (B). 
Evaluation of TMOD1 expression by primary tumoral size shows that the optimal cutoff 
point in the ROC curve analysis is 112.3 (AUC, 0.578; 95% CI, 0.496-0.660; sensitivity, 
70.7%; specificity, 52.4%). The TMOD1 OSCCs sq-IHC scores in T1/T2 and T3/T4 range 
from 204.44 to 7.00 (median, 87.46) and 201.67 to 20.00 (median, 113.13), respectively. 
The TMOD1 protein expression in the primary OSCCs does not differ significantly 
(p=0.057, Student’s t-test) between T1/T2 and T3/T4 (C). Evaluation of TMOD1 
expression in primary OSCCs by histologic type shows that the optimal cutoff point in 
the ROC curve analysis is 119.1 (AUC, 0.665; 95% CI, 0.489-0.841; sensitivity, 68.3%; 
specificity, 70.0%). The TMOD1 OSCCs sq-IHC scores in well/moderately differentiated 
OSCCs and poorly differentiated OSCCs range from 204.44 to 7.00 (median, 100.00) and 
193.17 to 34.50 (median, 138.14), respectively. The TMOD1 protein expression in the 
primary OSCCs does not differ significantly (p=0.073, Student’s t-test) between 
 well/moderately differentiated OSCCs and poorly differentiated OSCCs (D). Evaluation 
of TMOD1 expression in primary OSCCs by vascular invasiveness shows that the 
optimal cutoff point in the ROC curve analysis is 107.0 (AUC, 0.527; 95% CI, 
0.437-0.618; sensitivity, 60.4%; specificity, 60.0%). The TMOD1 OSCCs sq-IHC scores 
with/without vascular invasion range from 204.44 to 7.00 (median, 97.00) and 201.17 to 
12.50 (median, 108.53), respectively. The TMOD1 protein expression in the primary 
OSCCs does not differ significantly (p=0.558, Student’s t-test) with/without vascular 
invasion (E).  
 
Figure 4. Evaluation of TMOD1 expression in primary OSCCs by RLNM. ROC 
curve analysis shows that the optimal cutoff point is 100.00 (AUC, 0.608; 95% CI, 
0.527-0.688; sensitivity, 65.8%; specificity, 57.5%) (A). The TMOD1 OSCCs sq-IHC 
scores without RLNM and with RLNM range from 204.44 to 12.50 (median, 85.48) and 
201.17 to 7.00 (median, 112.16), respectively (B). The TMOD1 protein expression in the 
primary OSCCs with RLNM is significantly (p=0.0199, Student’s t-test) higher than 
those without RLNM. 
 
Figure 5. Evaluation of TMOD1 expression in primary OSCCs in patients with 5-year 
survival. Using the RLNM cutoff value from the ROC curve analysis, the TMOD1 
expression level is significantly (p=0.0064, log-rank test) correlated with the 5-year 
survival. The 5-year survival rates in the TMOD1-positive OSCCs (n=103) and the 
TMOD1-negative OSCCs (n=97) are 60.4% and 79.9%, respectively. 
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 Table 1. Clinical classification in OSCCs from 200 patients. 
Variable No. patients  (%) 
Age at surgery (years) 
  
  <70 111 55.5 
  ≧70 89 44.5 
Gender 
  
Male 132 66 
Female 68 34 
T-primary tumor 
  
T1+ T2 116 58 
T3+ T4 84 42 
N-regional lymph node 
 
Negative 120 60 
Positive 80 40 
Histopathologic type 
  
Well and moderately 
differentiated  
190 95 
Poorly differentiated 10 5 
Vascular invasion 
  
Negative 149 74.5 
Positive 51 25.5 
 
 Table 2. Prospective study of TMOD1 expression in primary OSCCs from 40 patients. 
Relative 
 expression 
RLNM 
(n=40) P value 
- (%) + (%) 
High TMOD1 9 (37.5%) 12 (75%) 
0.027 
Low TMOD1 15 (62.5%) 4 (25%) 
Total 24 (100%) 16 (100%) 
 
 
High TMOD1 expression is seen in 12 (75%) of 16 RLNM-positive patients and nine 
(37.5%) of 24 RLNM-negative patients. Low TMOD1 expression is seen in four (25%) of 
16 RLNM-positive patients and 15 (62.5%) of 24 RLNM-negative patients. 
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